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 Abstract 
1 
 
Acute lymphoblastic leukemia (ALL) is a type of cancer that affects immature 
lymphocytes developing in the bone marrow. Genetic susceptibility to leukemias can 
be related to the polymorphisms in CYP2D6 and CYP1A1 genes and consistent with 
this paradigm several polymorphisms have been identified in the pathogenesis of 
lymphoid malignancies.CYP2D6 and CYP1A1-
 
the member of the cytochrome P450 
mixed-function oxidase system, are the most important enzymes involved in the 
metabolism of various drugs in the body. To determine whether these genes played a 
similar role in childhood leukemogenesis in the Kashmiri children, we compared the 
allele frequencies of 120 childhood ALL patients and 110 controls for the CYP1A1 
and CYP2D6 genes. Genotyping was done by PCR-RFLP technique and results were 
validated by direct sequencing of the PCR products. We observed that the CYP2D6 
(G) allele frequency was 97.27% in the controls and 45% in cases and CYP2D6 (A) 
allele frequency was 2.72% in the controls and 55% in cases. While as in case of 
CYP1A1 the frequency of CYP1A1 (T) allele was 88.75% in the controls and 83.88% 
in cases and CYP1A1 (C) allele frequency was 11.25% in controls and 16.66% in 
cases. This difference in frequency was found to be statistically insignificant with a 
P>0.05. The CYP2D6 wild genotype frequency was found to be present in 33.33% of 
the cases and 96.36% of the controls, the hetero variant in 23.33% of the cases and 
1.82% of controls, and the mutant genotype in 43.33% of cases and 1.82% of 
controls. While as in case of CYP1A1, the wild genotype was found to be present in 
70.83% of cases and 85.45% in controls, the hetero genotype in 25% of the cases and 
22.73% of controls and the mutant was found to be present in 4.17% of the cases and 
0.9% of controls. We observed that an increased risk associated with CYP2D6 Mutant 
genotype 43.33% (OR = 68.90, 95% CI, 16.02-296.3;  P =  <0.0001 ) and Wild 
genotype 33.33% and  low with hetero genotype 23.33%  of CYP2D6 as compared to 
the controls and also increased risk is associated with CYP1A1 wild (T/T) genotype 
70.83 % and hetero 25%  (OR 1.33, 95% CI,  0.72- 2.43; P = 0.44) and low in case of 
mutant (C/C) genotype 4.17% ( OR = 5.53, CI 95% 0.63-48.31, P = 0.19) as 
compared to the controls. Thus, our study suggests that there is an association 
between gene polymorphism of CYP2D6 and CYP1A1 and the development of ALL 
in Kashmiri children.  
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he term 'leukemia' was coined in 1856 by the German pathologist Rudolph 
Virchow to describe a disease characterized by unusual quantities of white cells 
visible in the blood when studied under a microscope. Leukemia is no longer regarded 
as a single disease, but rather a collection of disorders with overlapping symptoms. 
Leukemia is a cancer arising from hematopoietic cell lines (Bloomfield et al., 2001) 
that produce blood cells. Leukemia is thus a hematological malignancy, in which 
malignant blood cells or their precursors proliferate without control and accumulate in 
bone marrow and blood resulting in abnormal blood cells.  Leukemia appears to be 
related to damage to chromosomes or genes (National Cancer Institute, 1996).The 
damage disrupts the process by which blood cells achieve their final and functional 
form. Leukemia  is the most common cancer in children accounting for about 1 out of 
3 cancers in children (American Cancer Society, 2012) and these are the leading 
cause of  cancer death in children under 15 years of age and  the  seventh  most 
common form of cancer death overall. 
 
 
(Courtesy: Tenin, 2003) 
Fig 1.1: Tentative scheme of Hematopoiesis 
 
 
 
T 
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Although the cause of Leukemia is uncertain, symptoms of the disease occur due to 
accumulation of immature blood cells in the bone marrow which prevents the normal 
production of red blood cells, white blood cells and platelets. Symptoms also include 
bruising, pallor, fatigue, fever, bone pain, and anorexia (Mulhern et al., 2003). 
Leukemia is often described as being either acute (fast growing) or chronic (slow 
growing). Almost all childhood leukemia is acute. 
 Acute leukemias 
There are two main types of acute leukemia: 
 Acute lymphocytic (lymphoblastic) leukemia (ALL): About 3 out of 4 
cases of childhood leukemia are ALL. This leukemia starts from the 
lymphoid cells in the bone marrow. 
 Acute myelogenous leukemia (AML): This type of leukemia, also called 
acute myeloid leukemia, acute myelocytic leukemia, or acute non-
lymphocytic leukemia, accounts for most of the remaining cases. AML 
starts from the myeloid cells that form white blood cells (other than 
lymphocytes), red blood cells, or platelets. 
 Hybrid or mixed lineage leukemias: In these rare leukemias, the cells have 
features of both ALL and AML. In children, they are generally treated like 
ALL and respond to treatment like ALL. 
 Chronic leukemias 
Chronic leukemias are much more common in adults than in children. They tend to 
grow more slowly than acute leukemias, but they are also harder to cure. Chronic 
leukemias can also be divided into two types: 
 Chronic myelogenous leukemia (CML): This leukemia rarely occur in 
children.  
 Chronic lymphocytic leukemia (CLL): This leukemia is extremely rare 
in children. 
 Juvenile myelomonocytic leukemia (JMML) 
This rare type of leukemia is neither chronic nor acute. It begins from myeloid cells, 
but it doesn’t grow as fast as AML or as slow as CML. It occurs most often in young 
children (under age four).  
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ALL is the single most common diagnosis in pediatric oncology. Half to two-thirds of 
all ALL cases occur in children. ALL comprises 75-80% of childhood acute 
leukemias, while 20% are acute myelocytic leukemia (AML) and the remaining cases 
are chronic myelocytic leukemia (CML approximately 2%) and myelodysplastic 
syndrome (MDS) (Pui et al., 1999). Acute leukemia accounts for only 2 percent of all 
cancers in the Unites States (Krajinovic et al., 2004). ALL can occur at any age of 
childhood, but is most common between the age of 2 and 3 years, with 50% of the 
patients <5 years of age (Gustafsson et al., 1998 and Sather et al., 1986). 
Although ALL is the most common type of leukemia in young children, but the 
disease also affects adults, especially those aged 65 years and older. Many people 
with ALL can be cured. However, despite the available treatments, ALL remains a 
serious and life-threatening disease in some patients (European Medicines Agency, 
2009). In patients under 15 years old, they account for over 30% of all malignant 
diseases (Pui et al., 2008). In the majority of cases of childhood leukemia, the cause 
is unknown. While a number of causes and highly suspected risk factors have been 
identified, reviews stress that these are responsible for only a very small number of 
cases. The known and highly suspected causes include genetic factors (2–3% of cases 
are associated with Down syndrome) and exposure to ionizing radiation in utero and 
after birth (Stiller et al., 2004 and Belson et al., 2007). Infectious diseases are likely 
to have a role in the etiology of childhood leukemia, especially ALL (Belson et al., 
2007 and O’Connor et al., 2007). Delayed exposure to infection during early infancy 
could result in an abnormal response, leading to development of leukemia. ALL could 
also be a rare response to a specific although unidentified infectious agent. Other 
environmental risk factors have been less clearly identified. The International Agency 
for Research on Cancer has concluded that extremely low-frequency electromagnetic 
fields are possibly carcinogenic to humans, based on consistent statistical associations 
of high-level residential magnetic fields with a doubling of risk of childhood leukemia 
(Lyon, International Agency for Research on Cancer, 2002). Several studies 
suggest that children exposed to certain hazardous chemicals have an increased risk of 
leukemia, with benzene being the most frequently suspected causal agent (Belson et 
al., 2007; Kingsley et al., 2007 and Holme et al., 2007). A number of papers have 
shown statistical associations between the risk of childhood leukemia and exposure to 
pesticides during pregnancy or childhood (Belson et al., 2007; Zahm et al., 1998; 
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Ma et al., 2002; Infante-Rivard et al., 2007 and Rudant et al., 2007). The risks 
associated with environmental leukemogens may be modified by genetic 
susceptibility (Infante-Rivard et al., 2007 and Urayama et al., 2007). A number of 
ecological studies show a positive correlation between leukemia, particularly ALL, 
and increasing socioeconomic status (Poole et al., 2006 and Committee on Medical 
Aspects of Radiation in the Environment, 2009). The reasons for this are not 
known. 
The etiology of the majority of ALL are unknown and commonly involve gene - 
environment interactions that may result in chromosome translocations, deletions and 
inversions (Skibola et al.,1999) but the development of ALL probably arises through 
the gene-environment interactions should not be fully understood and should be 
investigated  further (Greaves et al., 1997). The frequencies of the different subtypes 
of ALL have been related to different factors in different countries. Nevertheless, 
though individuals are exposed to these environmental and lifestyle risk factors. Acute 
leukemia develops only in a small proportion of the exposed people, indicating that 
the host genetic factors might play an important role in the genesis of leukemia. 
Several genetic variations have been evaluated as possible risk factors for leukemia by 
meta-analyses and various investigations have focused on the xenobiotic metabolism, 
DNA repair pathways, and cell-cycle checkpoint functions that might interact with 
environment, dietary, maternal, and external factors to affect the development of 
ALL. Previous evidence indicates that carcinogen-metabolizing genes may play 
critical role in determining individual susceptibility to malignancies (Boffetta et al., 
2010 and Klaunig et al., 2010). Genetic variations in these genes may change the 
activities of their encoded enzymes, possibly by altering their expression and 
function. A number of published studies support a possible role for polymorphism in 
genes encoding cytochrome P450, NAD(P)H quinineoxidoreductase, glutathione-S-
transferases, serine-hydroxymethyltransferases, methylenetetrahydrofolate reductase,  
cell cycle inhibitors and thymidylate synthase. Thus, different genetic polymorphisms 
exert different effect on acute lymphoblastic leukemia risk. Nevertheless, only a few 
gene polymorphisms associated with leukemia susceptibility have been identified. To 
explore the role of other genetic polymorphisms on the risk is required. 
Although the future looks promising with increasing knowledge of cancer biology and 
new treatment possibilities being developed, the etiology of the disease in Kashmir is 
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still a matter of speculation and proposed association with various environmental 
factors and genetic predisposition need to be deciphered. The understanding of the 
contribution of genetic predisposition with the malignancy can be extended to other 
regions in India and rest of the world particularly cancer belt regions and may be 
helpful in shifting from chemotherapy to chemoprevention. The study will pave way 
for other studies aimed at ascertaining the biomarkers for early detection and 
diagnosis. Hence, we are interested in understanding the status of these suspected 
polymorphisms that causes the inter-individual variability in drug response, 
influencing the treatment of several diseases. This necessitates the need for 
identifying the gene polymorphisms and also it will help in the development of most 
effective and specific drugs in ALL patients, as it has been rightly said: 
 
“Cancer is a word, not a sentence.” - John Diamond 
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ACUTE LYMPHOBLASTIC LEUKEMIA  
Acute lymphoblastic leukemia (ALL) is a malignant proliferation of lymphoid cells 
blocked at an early stage of differentiation. ALL is a biologically heterogeneous 
disorder characterized by morphologic, immunologic, cytogenetic, biochemical, and 
molecular genetics. Characterizations of leukemia lymphoblast are needed to establish 
the diagnosis or to exclude other possible causes of bone marrow failure and, finally, 
to classify ALL subtypes. This heterogeneity reflects the fact that leukemia may 
develop at any point during the multiple stages of normal lymphoid differentiation. 
2.1 Epidemiology of ALL  
Most ALL cases occur in children, with an incidence of 3 to 4/100,000 in patients 0 to 
14 years of age and ~1/100,000 in patients older than 15 years, in the United States 
(National Cancer Institute, 2009). ALL is the single most common diagnosis in 
pediatric oncology representing nearly one third of all pediatric cancers. In children, 
ALL represents 75% of all acute leukemias (which in turn represent 34% of all 
cancers in this age group), with a peak incidence at 2 to 5 years of age (Gurney et al., 
1995). This percentage is much lower in adults, in whom acute myeloid leukemias 
(AMLs) and chronic lymphocytic leukemias are more common (Gurney et al., 
1995)(American Cancer Society, 2009). There is a slight male predominance in all 
age groups and a significant excess incidence among white children (National 
Cancer Institute, 2009). The incidence of ALL, particularly T-cell ALL, is slightly 
higher among boys than girls (Kersey et al., 1973; Zahm and Devesa, 1995; Ries et 
al., 1998 and Margolin et al., 2001). Girls, however, have a higher incidence of all 
leukemias during the first year of life (Gurney et al., 1995 and Ries et al., 1998). 
ALL presents primarily as de novo disease, with only rare cases occurring as 
secondary neoplasm (Shivakumar et al., 2008). A variety of genetic and 
environmental factors have been related to ALL. It occurs with increased frequency in 
patients with Down syndrome, Bloom syndrome, neurofibromatosis type I (NF1) and 
ataxia telangiectasia (Spector et al., 2006). In addition, exposure in utero to ionizing 
radiation, pesticides, and solvents have also been related to an increased risk for 
childhood leukemia (Spector et al., 2006). Leukemia-specific fusion genes or 
immunoglobulin (Ig) and clonal Ig gene rearrangements have been identified in 
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neonatal spot (Guthrie) cards of patients who later developed ALL (Gale et al., 1997 
and Taub et al., 2002). 
Geographical differences in the incidence, age distribution and subtypes of childhood 
leukemia are found among countries in different parts of the world (Gustafsson et al., 
1982; Miller et al., 1995 and Swensen et al., 1997).The reported incidence rates are 
highest in Costa Rica, Australia, United States (among white children) and Germany. 
The rates are intermediate in most European countries and lowest in India and among 
black children in the United States (Parkin et al., 1988 and Gurney et al., 1995).   
2.2 CLASSIFICATION 
Acute lymphoblastic leukemia (ALL) encompasses a group of lymphoid neoplasms 
that morphologically and immunophenotypically resemble B-lineage and T-lineage 
precursor cells. These neoplasms may present predominantly as a leukemic process, 
with extensive involvement of the bone marrow and peripheral blood or may be 
limited to tissue infiltration, with absent or only limited (less than 25%) bone marrow 
involvement. The latter cases are typically designated as lymphoblastic lymphomas 
(LBLs). The current World Health Organization Classification of hematopoietic 
neoplasms designates these disorders as B- or T-lymphoblastic leukemia/lymphoma 
(Swerdlow et al., 2008). Acute leukemia can be classified in many ways: (1) By 
morphology and cytochemistry supplemented by immunophenotyping, as proposed 
by French-American-British (FAB) group (Bennet et al., 1976) (2) Proposed World 
Health Organization Classification of Acute Leukemia (Harris et al., 1999) (3) By 
immunophenotyping alone, as proposed by the European Group for the 
immunological classification of leukemias (EGIL) (Bene et al., 1995 and Hayhoe et 
al., 1988). 
2.2.1 French-American-British Classification.  
In the 1970s, a group of French- American and British (FAB) leukemia experts 
divided ALL into 3 subtypes (L1, L2 and L3), based on the way the leukemia cells 
looked under the microscope after routine staining. Acute lymphoblastic leukemia 
(ALL) is divided in FAB L1 (children), L2 (older children and adult), and L3 (patients 
with leukemia secondary to Burkitt's lymphoma. These types are defined according to 
two criteria (1) the occurrence of individual cytological features and (2) the degree of 
heterogeneity among the leukemic cells. The features considered are cell size, 
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chromatin, nuclear shape, nucleoli, degree of basophilia in the cytoplasm and the 
presence of cytoplasmic vacuolation (Bennett et al., 1976). 
 ALL-L1: Homogenous cells (Small cell): One population of cells within the 
case. Small cells predominant, nuclear shape is regular with occasional cleft. 
Nuclear contents are rarely visible. Cytoplasm is moderately basophilic. L1 
accounts 70% of patients. The L1 type is the acute leukemia that is common in 
childhood, with 74% of these cases occurring in children 15 years of age or 
younger. 
 ALL-L2: Heterogeneous cells: Large cells with an irregular nuclear shape, 
cleft in the nucleus are common. One or more large nucleoli are visible. 
Cytoplasm varies in colour and nuclear membrane irregularities. L2 accounts 
27% of ALL patients. The FAB-L2 blast may be confused with the blasts of 
acute myeloid leukemia. Approximately 66% of these cases of ALL in patients 
older than 15 years are of type 2. 
 ALL-L3: Burkitt's lymphoma type: Cells are large and homogenous in size, 
nuclear shape is round or oval. One to three prominent nucleoli and sometimes 
to 5 nucleoli are visible. Cytoplasm is deeply basophilic with vacuoles often 
prominent. Intense cytoplasmic basophilia is present in every cell, with 
prominent vacuolation in most. A high mitotic index is characteristic with 
presence of varying degrees of macrophage activity. Mature B-Lymphoid 
markers are expressed by most cases. 
The World Health Organization (WHO) classification has changed the grouping of 
ALL to reflect increased understanding of the biology and molecular pathogenesis of 
the diseases. In addition to discarding the L1-L3 terms, the new classification 
characterizes these heterogenous diseases based upon immunophenotype into 3 basic 
categories: precursor B-cell ALL, precursor T-cell ALL and mature B-cell ALL 
(Burkitt lymphoma/leukemia) (Jaffe et al., 2001).                    
2.2.2 European Group for the Immunological classification of Leukemias (EGIL) 
Immunologic surface and cytoplasmic marker studies are of great significance for 
classification of acute Lymphoblastic leukemias. The European Group for the 
Immunological Classification of Leukemias (EGIL) (Bene et al., 1995 and Hoelzer 
et al., 2002) has proposed that ALL be classified on the basis of immunophenotype 
alone. Initial attempts to classify ALL stemmed from the observation that 
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lymphoblasts and normal lymphoid precursors express common antigens. Based on 
the expression of these antigens, the consensus considers a 20% minimum threshold 
to define a positive reaction of blast cells to a given monoclonal antibody. 
The earliest B-lineage markers are CD19, CD22 (membrane and cytoplasm) and 
CD79a (Campana et al., 1988). A positive reaction for any two of these three 
markers, without further differentiation markers, identifies pro-B ALL. The presence 
of CD10 antigen (CALLA) defines the "common" ALL subgroup. Cases with 
additional identification of cytoplasmatic IgM constitute the pre-B group, whereas the 
presence of surface immunglobulin light chains defines mature B-ALL. 
T-cell ALL constitute approximately 25% of all adult cases of ALL. T-cell markers 
are CD1a, CD2, CD3 (membrane and cytoplasm), CD4, CD5, CD7, CD8, CD2, CD5 
and CD7 antigens are the most immature T-cell markers, but none of them is 
absolutely lineage specific, so that the unequivocal diagnosis of T-ALL rests on the 
demonstration of surface/cytoplasmic CD3. 
ALL of B or T lineage can additionally express stem-cell antigen CD34. It has little 
diagnostic relevance but can be prognostically important (De Waele et al., 2001).The 
scoring system recently proposed by the EGIL group addressed the characterization of 
the acute lymphoblastic leukemia as B or T lineage ALL by including the most 
specific markers for the lymphoid lineages among those of earlier stages of cell 
differentiation and some non-specific but stem-cell markers. The system introduced a 
modified terminology specific to each 'maturation' step within the B- or T-cell lineage 
(EGIL, 1995) and was confirmed as adequate for both diagnosis and sub 
classification of ALL (Thalhammer-Scherrer et al., 2002). 
2.3 CYTOGENETICS IN ALL 
ALL is a group of cytogenetically distinct diseases related to clinical characteristics. 
The cytogenetic grouping of ALL facilitates understanding of the differences in 
etiology and epidemiology of different disease subtypes. The main reasons for 
performing cytogenetic analysis in ALL include obtaining information on prognosis 
and monitoring the disease and MRD status at levels beyond the sensitivity of 
cytomorphologic methods. Recurrent genetic abnormalities are hallmark of acute 
leukemia and provide insights into the molecular mechanisms of leukemogenesis 
(Armstrong  et al., 2005). The most frequent targets of genetic alterations involved in 
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hematological disorders are genes controlling transcription and tyrosine kinases 
(Mitelman et al., 2004). The large variety of genetic alterations includes point 
mutations and deletions, but the main genetic characteristics of acute leukemia are 
translocations and numerical chromosome imbalances resulting in hyper or 
hypodiploidy. These chromosomally defined subtypes also show distinctive patterns 
of global gene expression in microarray analysis (Greaves and Wiemels et al., 
2003). 
2.3.1 CHROMOSOMAL TRANSLOCATIONS 
Cytogenetic analyses of childhood ALL have been found to be of both biological and 
clinical importance, and banded karyotyping is today part of the routine diagnostic 
procedure. Chromosomal aberrations in ALL can be divided into two groups, which 
can be present simultaneously: Abnormalities in the number of chromosomes (ploidy) 
and structural aberrations, such as translocations, deletions, partial duplications, 
inversions, and dendritic chromosomes. During the last three decades, numerous 
primary and secondary, chromosomal abnormalities, both numerical and structural, 
have been described in ALL and also shown to correlate to clinical parameters and 
outcome (Mitelman et al., 1997 and Mitelman et al., 2002). 
Two of the most constant findings are that hypodiploidy (less than 46 chromosomes 
per cell) and presence of Philadelphia chromosome are risk factors for treatment 
failure. Massive hyperdiploidy in ALL (greater than 50 chromosomes per cell), a 
typical childhood feature in this disease (1-10 years of age), has shown different 
degrees of impact on the prognosis with differences in treatment intensity, although in 
most studies it has been shown to be an indicator of a lower risk for treatment failure. 
Chromosome translocations either result in inappropriate expression of an oncogene 
by juxtaposition of the entire coding sequence under constitutive activated regulatory 
elements of a partner gene or more commonly in leukemia in the formation of a 
chimeric fusion gene with novel properties. An increasing number of promiscuous 
genes (e.g. MLL, ETV6 or NUP98) that recombine with numerous different partner 
genes have been identified and, thus, the number of fusion genes exceeds the number 
of affected genes.  
In childhood BCP-ALL the most common genetic rearrangement is the t(12;21) 
(p13;q22), which fuses ETV6 to RUNX1 and is present in about 25% of BCP-ALL 
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cases.Fig.2.1(Armstrong et al., 2005). Other commonly found chromosomal 
aberrations in childhood ALL are the t (1; 19) (q23; p13)/ E2A-PBX1 (TCF3-PBX1), 
the t(9;22)(q34;q11)/BCR-ABL1, and hyperdiploidy (presence of greater than 46 
chromosomes), which is often associated with a FLT3 mutation (Fig. 5) (Armstrong 
et al., 2005). Rearrangements of the MLL gene occur in up to 80% of infant ALL and 
are associated with a pro-B ALL phenotype (Attarbaschi et al., 2006; O'Neil and 
Look et al., 2007 and Pieters et al., 2007). 
 
Figure 2.1: Pie diagram showing relative frequencies of chromosomal aberrations 
found in childhood B-ALL (Armstrong et al., 2005). 
Recently, pediatric ALL was further characterized by genome-wide analyses using 
high resolution SNP arrays and DNA sequencing, which uncovered that in about 40% 
of BCP-ALL genes implicated in B-cell development and differentiation are targets of 
mutations, deletions or structural rearrangements (Mullighan et al., 2007). These 
genes comprised IKZF1 (Ikaros), IKZF3 (Aiolos), LEF1, EBF1, TCF3 (E2A), and 
PAX5 (Kuiper et al., 2007 and Mullighan et al., 2007). In addition to micro 
deletions in transcription factors involved in B-lineage development, recurrent 
deletion of BTG1 a negative effector of B-cell proliferation was observed. Moreover, 
other genes frequently affected by copy number losses were those controlling G1/S 
cell cycle progression (e.g. CDKN2A, CDKN2B, and RB1), and such deletions were 
detected in 54% of BCP-ALL and 86% of T-ALL, respectively (Kuiper et al., 2007). 
BCP-ALL, analysis of neonatal blood spots for leukemia specific rearrangements 
showed that most T-ALL cases are more likely initiated postnatally (Fischer et al., 
2007). Interestingly, the ETV6-RUNX1 and the RUNX1-RUNX1T1 (AML1-ETO) 
fusion genes could be detected 100 times more often in blood samples from healthy 
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newborns as the risk of the corresponding leukemia (Mori et al., 2002). The ETV6-
RUNX1 positive leukemic blasts of the twin diagnosed with full-blown BCP-ALL 
showed a deletion of the second ETV6 allele, whereas the ETV6-RUNX1 positive cells 
of the healthy twin harbored one intact copy of ETV6. These data strongly support the 
notion that inactivation of the second unrearranged ETV6 allele indeed represents a 
crucial cooperating mutation (Hong et al., 2008). 
2.3.2 COOPERATIVE MUTATIONS 
Although fusion oncogenes encoded by chromosomal translocations are a hallmark of 
pathogenesis of ALL. It seems likely that other genetic lesions are also needed to 
induce overt leukemia (Knudson et al., 1971). A well-characterized example is the 
deletion or epigenetic silencing of the cyclin-dependent kinase inhibitor 2A gene 
(CDKN2A) located in 9p21.3.This gene encodes the tumor suppressors p16INK4A 
and p14ARF (Lukas et al., 1995 and Stott et al., 1998). Inactivation of this gene 
neutralizes both the TP53 and retinoblastoma pathways, which control the transition 
of cell cycle from G1 phase to S phase, thus serving as tumor suppressor proteins. 
Deletions of CDKN2A are present in about 70% of T-ALL and 30% of B-cell 
precursor ALL (Bertin et al., 2003). 
 
Fig 2.2: The Retinoblastoma pathway and p53 Tumor suppressor 
cross talk (Pui et al., 2004). 
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NOTCH1 has been identified as a partner gene in t (7; 9), found in less than 1% of T-
ALL cases (Ellisen et al., 1991). It encodes a transmembrane receptor that regulates 
normal T-cell development (Maillard et al., 2005). Despite the rare involvement of 
NOTCH1 in translocations, recent studies have shown its importance in T-ALL 
through activating mutations. Such mutations involving NOTCH1 are present in more 
than 50% of T-ALL patients (Weng et al., 2004; Grabher et al., 2006 and Marks et 
al., 2009). The mechanisms by which aberrant NOTCH signaling causes T-ALL 
remain unclear. Expression of oncogenes, such as MYC, probably plays an important 
role. Evidence suggests that the MYC oncoprotein is an important downstream 
mediator of the pro-growth effects of NOTCH1 signaling in the developing 
thymocytes (Weng et al., 2004). Activating mutations in NOTCH1 can induce T-ALL 
in experimental models and could be the initiatory event in most human T-cell 
leukemias (Grabher et al., 2006). 
 
 
 
Fig 2.3: Notch signaling pathway in normal thymocytes (Pui et al., 2008) 
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2.4 ETIOLOGY OF LEUKEMIA 
ALL is a heterogeneous grouping of biological subtype of leukemias and smaller 
studies of the past may have lacked sufficient statistical power to examine potential 
risk factors. Thus, one emerging theme concerning the etiology of childhood ALL is 
the need to separately study different biological groups of ALL. Epidemiologic 
studies of acute lymphoblastic leukemia in children have examined several internal 
and external risk factors for childhood ALL. These factors included a number of 
possible risk factors e.g., environmental, dietary, socioeconomic, genetic or 
immunological factors in an effort to determine the etiology of the disease. 
Knowledge of these particular risk factors can be used to support measures to reduce 
potentially harmful exposures and decrease the risk of disease.  
2.4.1 ENVIRONMENTAL FACTORS 
2.4.1.1 Ionizing radiations 
Large epidemiological studies have documented that ionizing radiation under certain 
conditions of exposure induces human cancers including Acute lymphoblastic 
leukemia (Jablon et al., 1970 and Black et al., 1987). Ionizing radiation is one of the 
few exposures for which the causal relationship with childhood leukemia, particularly 
AML, has been established (Ron et al., 1998; Sali et al., 1996; United Nations 
Scientific Committee on the Effects of Atomic Radiation, 1994 and Mahoney et 
al., 2004). Currently, in utero low-dose ionizing radiation exposure is recognized as 
an established risk factor for childhood cancers under the assumption that the fetus 
may be more susceptible to the leukemogenic effects of radiation than the child. The 
magnitude of the risk depends on the dose of radiation, the duration of exposure, and 
the age of the individual at the time of exposure. Studies have demonstrated the 
relationship between the degree of irradiation and occurrence of leukemia (Moloney 
et al., 1955 and Miller et al., 1967). The potential effect of ionizing radiation 
exposure on children may occur during preconception, pregnancy, or the postnatal 
period. 
2.4.1.2 Non- Ionizing Radiations  
Numerous epidemiologic studies have reported associations between measures of 
power-line electric or magnetic fields (EMFs) and childhood leukemia. The basis for 
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such association remains unexplained some studies have found a small association, 
(Savitz et al., 1990; Hatch et al., 1998; Ahlbom et al., 2000; Greenland et al., 
2000; Rivard et al., 2003) while others have not (Myers et al., 1990; Linet et al., 
1997 and Kleinerman et al., 2000). The inconsistent results of the EMF and 
childhood leukemia studies may be due in part to differing methods for assessing 
residential magnetic field exposures and unmeasured EMF characteristics (Hardell et 
al., 1995; Bowman et al., 2001; Brain et al., 2003). Furthermore, investigations of 
animals with exposure to much higher levels of EMFs than humans have not shown 
increased risk for hematopoietic neoplasia (Brain et al., 2003). 
2.4.1.3 Chemicals 
Parental occupational exposure to chlorinated solvents, paints or thinners and plastic 
materials could cause leukemia in children. Parental occupational exposure to some 
certain chemicals like benzene can trigger the development of acute lymphoblastic 
leukemia in their offspring (Greaves et al., 2002). A recent occupational study (Glass 
et al., 2003) found excess risk for leukemia associated with cumulative benzene 
exposures and benzene exposure intensities at lower levels (less than 60 ppm-years) 
than had been previously reported (as high as 220 ppm-years) (Belson et al., 2007). 
Some studies have investigated the possible etiologic factors for childhood leukaemia 
related to parents occupational and home exposures (Lowengart et al., 1987 and Shu 
et al., 1999).The results indicated an increased risk of leukemia for children whose 
father had an occupational exposure after the birth of the child to chlorinated solvents, 
spray paint, dyes or pigments, methyl ethyl ketone, and cutting oil. 
2.4.1.4 Pesticides 
There is growing evidence in support of the association between pesticide exposure 
and childhood leukemia. Most of the studies evaluating exposure to household 
pesticides and risk of childhood leukemia suggest that an increased risk is associated 
with in utero and postnatal pesticide exposures (Ma et al., 2002). This suggests that 
newborns and children may be particularly sensitive to the carcinogenic effects of 
pesticides (National Research Council, 1993 and Zahm et al., 1998). Most children 
exposure to pesticides is from home, lawn and garden use (Grossman et al., 1995). 
Other sources of exposure can include local agricultural applications, contaminated 
food, parental occupation, and pet products. Some studies have reported increased risk 
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with mothers, who had frequent prenatal pesticide exposure in the garden (Infante-
Rivard et al., 1999) or during Pregnancy (Lowengart et al., 1987) and increased risk 
during childhood with garden insecticides and garden fungicides (Menegaux et al., 
2006). 
2.4.1.5 Alcohol cigarette and illicit drug use 
The passive smoking literature is inconsistent regarding an association of maternal or 
paternal smoking on the risk of childhood ALL. It is unclear whether maternal or 
paternal cigarette smoking before or during pregnancy is a risk factor for developing 
childhood leukemia (Shu et al., 1996 and Brondum et al., 1999). Some studies have 
reported that parental smoking, either maternal, paternal, or both, had a significant 
effect on childhood acute leukemia (Ji et al., 1997) while other studies found no 
association between parental smoking and childhood leukemia (Pang et al., 2003). 
Two studies found that the frequency, amount and duration of paternal smoking 
before conception were related to significantly elevated risk, after adjusting for the 
effect of maternal smoking (Sorahan et al., 1995; Ji et al., 1997 and Brondum et 
al., 1999) however, found no association between the disease and paternal smoking at 
any time. 
2.4.2 DIETARY FACTORS 
There has been little systematic research on maternal dietary factors in childhood 
ALL. Most studies of maternal diet have focused on specific food groups such as 
vitamins A and D, (Shu et al., 1988), cured meats, (Blot et al., 1999), 
supplementation with folate (Thompson et al., 2001) or foods containing 
topoisomerase II inhibitors and their relationship to childhood acute lymphoblastic 
leukemia. Cured meats, which contain N-nitroso precursors that can be converted to 
carcinogenic N-nitroso compounds in an acidic environment, have been hypothesized 
to increase the risk of childhood leukemia either through maternal consumption 
during pregnancy or child consumption early in life (Blot et al., 1999). Another study 
have shown that there is a significant positive association of childhood ALL with 
increasing consumption of DNA topoisomerase II inhibitor-containing foods such as 
beans, fresh vegetables, canned vegetables, fruit, soy, regular coffee, black tea, cocoa 
and wine (Ross et al., 1996). 
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2.4.3 IMMUNOLOGIC FACTORS AND POPULATION MIXING THEORY 
Several studies contribute to the theory that a transmissible agent is potentially 
involved in the oncogenic process of childhood acute lymphoblastic leukemia. Some 
studies showed that the peak incidence of childhood ALL and that of common 
childhood infections both occur among children 2–5 years of age, as this age group 
possess sophisticated immune systems (Greaves et al., 2002).While some showed 
viral etiology associated with some human cancers (e.g., Epstein-Barr virus for 
Burkitt lymphoma) (Greaves and Alexander et al., 1993) (Kinlen et al., 
1995).Susceptible individuals who live in rural areas in which the population 
suddenly increases, or for which the composition changes regularly, may be exposed 
to infectious agents that are brought into the area by new residents, possibly triggering 
a cluster of cases of ALL. The theory implies that the differences in rates of leukemia 
in rural areas are due to differences in herd, or population, immunity. Results from 
other studies support this theory (Kinlen et al., 1995; Alexander et al., 1997; 
Gilman et al, 1998; Koushik et al., 2001 and Boutou et al., 2002). 
Kinlen (1995) hypothesized that increased rates of leukemias are seen following 
periods of population mixing, which can introduce new infectious agents into a 
community of individuals who were previously unexposed or who may have 
susceptibility to the infectious agent. Similarly, Greaves (1988 and 1997) 
hypothesized that the development of leukemia is related to inadequate development 
of the infant’s immune response or to a lack of exposure to infections in early 
childhood, resulting in an abnormal immune response. When these children are later 
exposed to common infections (the “delayed infection” hypothesis). Down’s 
syndrome has also been associated with an increased risk of pediatric leukemia (Taub 
et al., 2001 and Reynold et al., 2002).  
2.4.4 SOCIO-ECONOMIC STATUS 
In the vast majority of the epidemiologic studies focusing on childhood ALL, the role 
of socioeconomic status (SES) in the causal pathway is controversial. Early ecologic 
and descriptive studies from the United States suggested that higher SES was a 
possible risk factor for childhood leukemia while early United Kingdom studies 
reported mixed results (Reinier et al., 2002). Pelin (2002) in his study observed that 
the socioeconomic status of the patients and the control group did not show a 
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significant difference, with approximately 75% belonging to lower socio-economic 
status. 
2.4.5 GENETIC FACTORS  
Genetic factors ranging from predisposing highly penetrant mutations to low 
penetrant genetic polymorphisms have been shown to significantly influence the 
interindividual variation in cancer incidence (Shields et al., 2000). Therefore several 
internal and external risk factors contribute to root cause of cancer development i.e 
activation of oncogenes and inactivation of defense genes (Nishihira et al., 1993). 
Certain gene polymorphisms have been shown to alter the risk of development of 
leukemia and these variations can interact with diet, other environmental exposures, 
and individual immune function to be major determinants of susceptibility. However, 
clonal evolution, characterized by complex karyotypic changes and the modest 
concordance rate for ALL in identical twins strongly suggest that additional genetic 
events, occurring mainly in the postnatal period, are required for progression to full 
malignancy (Greaves et al., 1999). Consistent with this paradigm, several genetic 
alterations, due to incorrect DNA synthesis or altered methylation status of oncogenes 
and/or tumor suppressor genes, have been identified in the pathogenesis of lymphoid 
malignancies (Zing et al., 1997; Kuppers et al., 1999 and Vanesse et al., 1999). 
2.4.6 FOLATE-METABOLIZING ENZYMES 
The folate cycle is important in DNA synthesis, DNA repair and DNA methylation. 
Methylenetetrahydrofolate reductase (MTHFR) has a major impact on the regulation 
of the folic acid pathway due to the conversion of 5, 10 methylenetetrahydrofolate 
(methylene-THF) to 5-methyl-THF. The two common polymorphisms of the MTHFR 
gene are 677 C→T and 1298 A→C, which are known to reduce the enzyme activity, 
leading to a decreased pool of methyl-THF particularly in the folate-deficient states. 
The polymorphic forms of MTHFR increase the level of methylene -THF leading to a 
subsequent reduction of uracil in DNA, protecting the DNA from double stranded 
breaks and consequently from chromosomal alterations (Blount et al., 1997). 
MTHFR variants are known to influence disease processes and several studies in 
literature have reported on reduced MTHFR activity and susceptibility to lymphoid 
malignancies. MTHFR, either heterozygous and / or homozygous for 677T and 
1298C polymorphisms have been shown to reduce the risk of ALL (Chatzidakis et 
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al., 2006 and Kamel et al., 2007), while other studies have found no association 
(Chiusolo et al., 2004; Schnakenberg et al., 2005 and Thirumaran et al., 2005). 
Some studies found a protective role of T677 and C1298 variants in a subset of 
childhood leukemias (Skibola et al., 1999; Smith et al., 1999 and Wiemels et al., 
2001) whereas, some observed the protective effect only for the MTHFR 677 
homozygous (TT) genotype (Franco et al., 2001). On the other hand, studies from 
India and Philippines have reported an increased risk of ALL among children for both 
polymorphisms (Reddy et al., 2006 and Alcasabas et al., 2008). There have been 
several published studies with contradicting results of association between MTHFR 
polymorphisms and acute lymphoblastic leukemia. Multiple factors could be the 
reason for the difference between the observations in this study and results reported 
by others. Those include differences in ethnicity, gene-gene interaction, and gene 
environment interaction but it may be associated with increasing the risk for ALL. 
These results need to be confirmed by a larger sample size. 
2.4.7 XENOBIOTIC METABOLIZING ENZYMES 
Genetic susceptibility studies of genes that encode enzymes with critical roles in 
xenobiotic metabolism and membrane transport have shown associations with an 
increased risk of childhood acute lymphoblastic leukemia (Chen et al., 1997; 
Krajinovic et al., 1999; Wiemels et al., 1999; Infante-Rivard et al., 2000; 
Krajinovic et al., 2000; Saadat et al., 2000; Franco et al., 2001; Krajinovic et al., 
2002; Smith et al., 2002; Canalle et al., 2004 and Jamroziak et al., 2004). The 
complete metabolism of xenobiotic compounds is divided into two phases, each 
utilizing different sets of metabolic enzymes. The metabolic activation of the 
xenobiotics performed by the phase I enzymes are usually necessary in order for the 
phase II enzymes to convert this activated intermediate into a detoxified water soluble 
compound that can be easily eliminated from the cell (Lang et al., 1999). Genetic 
polymorphisms that disrupt the equilibrium between these two phases compromise the 
host’s ability to respond appropriately to several xenobiotics which may potentially 
increase the host’s susceptibility to develop cancer. 
The cytochrome P450 is a member of superfamily heme-thioloate monooxygenase 
enzymes (EC 1.14.14.1) that is involved in the oxidative metabolism of a number of 
endogenous and exogenous compounds like steroids, drugs, carcinogens and 
mutagens. In humans, 57 functional CYP450 genes and 58 pseudogenes have been 
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described (Nelson et al., 2004 and Guengerich et al., 2008).The liver expressing 
CYP450 variants including many non-drug and drug metabolizing enzymes (Figure 2.4 
A). Of the drug metabolizing CYP450 variants, the clinically important ones include 
phase I drug metabolizing enzymes (DMEs) like CYP1A1, CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, CYP2E1, CYP3A4, CYP3A5 and CYP2D6 (Figure 2. 
4 B). 
           
  
 
Fig 2.4: Pie diagram showing the relative abundance of human P450 enzymes in the 
liver (A) and the percentage of pharmaceuticals metabolized by respective P450 
enzymes (B). 
 
The drug metabolizing CYP450s are responsible for the metabolism of 40-45% of all 
marketed drugs and 70-80% of all phase I dependent drug metabolism (Ingelman-
Sundberg and Rodriguez-Antona et al., 2005 and Guengerich et al., 2008).The 
activity of these CYP450 enzymes determine: (1) The rate of biotransformation of a 
parent drug into active and/or inactive metabolites. (2) The concentration of the drug 
and/or its metabolites that will be achieved in the body and (3) the rate of elimination 
of the drug and its metabolites. 
Children may be particularly vulnerable to environmental toxins because of their 
greater relative exposure, immature metabolism and higher rate of cell division and 
growth. In this context, functional polymorphisms in xenobiotic metabolizing 
enzymes have been postulated to be of relevance in determining susceptibility to ALL 
(Perera et al., 1997).These enzymes interact with environmental, dietary, maternal 
and other external and internal factors that affect the development of ALL. For 
example, inactivating polymorphisms of detoxifying enzymes (e.g., glutathione S-
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transferase, reduced nicotinamide adenine dinucleotide phosphate: quinineoxido-
reductase) have been variously associated with the development of ALL. However, 
these findings need to be confirmed by larger studies with careful attention to ethnic 
and geographic diversity in the frequency of polymorphisms (Pui et al., 2004). 
2.5 HUMAN CYTOCHROME P4502D6 GENE 
Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) is the first 
identified enzyme controlled by single gene located on the long arm of chromosome 
22q13, encoding protein of 497 amino acids (Zhou et al., 2009). It is the most 
polymorphic gene of metabolic enzymes so far, metabolizing nearly 20%~25% drugs 
in clinically with large individual differences (Kimura et al., 1989; Wilkinson et al., 
2005 and Sistonen et al., 2007). It accounts for about 2% of all hepatic P450s, but its 
role in drug metabolism is extensively higher than its relative content, metabolizing 
about 20-30% of all drugs on the market. In other words, it can be called a high-
affinity low capacity enzyme. The polymorphism of CYP2D6 was independently 
discovered in three different labs (Mahgoub et al., 1977; Tucker et al., 1977 and 
Eichelbaum et al., 1979). 
The CYP2D6 function in any particular subject may be described as one of the 
following:  
 Poor metaboliser–these subjects have little or no CYP2D6 function. 
 Intermediate metabolizers–these subjects metabolize drugs at a rate 
somewhere between the poor and extensive metabolizers. 
 Extensive metaboliser–these subjects have normal CYP2D6 function. 
 Ultrarapid metaboliser–these subjects have multiple copies of the CYP2D6 
gene expressed, and therefore greater-than-normal CYP2D6 function. 
The type of CYP2D6 function of an individual may influence the person's response to 
different doses of drugs that CYP2D6 metabolizes. The nature of the effect on the 
drug response depends not only on the type of CYP2D6 function, but also on the 
extent to which processing of the drug by CYP2D6 results in a chemical that has an 
effect that is similar, stronger, or weaker than the original drug, or no effect at all. For 
example, if CYP2D6 converts a drug that has a strong effect into a substance that has 
a weaker effect, then poor metabolizers (weak CYP2D6 function) will have an 
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exaggerated response to the drug and stronger side-effects; conversely, if CYP2D6 
converts a different drug into a substance that has a greater effect than its parent 
chemical, then extensive metabolizers (strong CYP2D6 function) will have an 
exaggerated response to the drug and stronger side-effects (Lynch et al., 2007). 
 
CYP2D6 GENE STRUCTURE 
CYP2D6 belongs to the CYP2D gene family. The CYP2D gene cluster which is 
located on chromosome 22q13.1 (Kimura et al., 1989) consists of three genes: (1) 
CYP2D6, a functional gene (2) CYP2D8, a pseudogene that arose by gene 
conversion, and (3) CYP2D7, a nonfunctional gene that arose by gene duplication 
(Figure 2.5). In the CYP2D family, CYP2D6 is the only gene that encodes a 
functional enzyme (Gaedigk et al., 2005). The wild type CYP2D6 gene is ~4.4 kb 
long. It is composed of 9 exons and a 1491 bp long open reading frame (ORF) that 
translates into a protein with 497 amino acids (Kimura et al., 1989). Many alternative 
spliced transcript variants that encode different isoforms have also been reported. The 
CYP2D6 gene is highly polymorphic; these polymorphisms affect the 
pharmacokinetics, metabolism, safety and efficacy of drugs that are metabolized by it 
(Ingelman-Sundberg et al., 2005). 
 
Fig 2.5: Representative picture of CYP2D6 gene, the brown boxes represent the 
exons and the white boxes represent the untranslated regions (UTRs). Some of the 
CYP2D6 representative variants are also shown; del denotes deletion; > denotes 
conversion. 
The CYP2D6 gene is not highly conserved across species. The rat and mouse 
orthologs equivalent to human CYP2D6 are cyp2d1 and cyp2d22, respectively. 
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Among these three species, the drug metabolism profile is very different. They exhibit 
variability in substrate specificity and also enzyme inhibition (Bogaards et al., 2000). 
Among rats and mice, there is also considerable inter strain difference in the 
metabolic profile (Corchero et al., 2001). For example, debrisoquine, a CYP2D6 
substrate drug, is metabolized to 4-hydroxy debrisoquine by humans and Sprague-
Dawley rats, but not by Dark Agouti rats, or by C57BL/6, DBA/2 and ddY strains of 
mice (Al-Dabbagh et al., 1981 and Masubuchi et al., 1997). Hence, model 
organisms are generally considered to be inadequate for preclinical studies of 
CYP2D6 substrate drugs. However, a humanized CYP2D6 transgenic mouse model is 
now available and has been shown to be a good experimental model resembling the 
human extensive metabolizer phenotype for some drugs, including debrisoquine 
(Corchero et al., 2001). 
CYP2D6 GENE POLYMORPHISMS 
CYP2D6 is a highly polymorphic gene. So far, more than 78 alleles and allelic 
subvariants have been identified (Human Cytochrome P450 Allele Nomenclature 
Committee: www.cypalleles.ki.se/cyp2d6.htm). 
These alleles can be classified as:  
 Functional alleles, with normal enzyme activity (e.g., CYP2D6*1, *2, *35, 
etc.)  
 Reduced functional alleles, with decreased enzyme activity (e.g., CYP2D6*9, 
*10, *17, *29, *37, *41, etc.) and  
 Nonfunctional alleles, with negligible enzyme activity (e.g., CYP2D6* 3-*8, 
*11- *16, *18-*20, *36, *38, *40, *42 etc.).  
A CYP2D6 star-allele represents either a single genetic variant or a haplotype that 
results in amino acid substitution, post-transcriptional modification, post-translational 
modification, and alteration in transcription, splicing, or translation (Robarge et al., 
2007). CYP2D6*1 is the wildtype reference sequence to which all the variants are 
compared. As new nucleotide variants (either a single variant or a combination of 
variants) are identified, a unique number is assigned (e.g., CYP2D6*2, *4, *10, etc) 
Fig.2.6 
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Fig 2.6: X represents single nucleotide polymorphisms (SNP) that are 
used for genotyping; X represents some of the representative SNPs present 
in the given CYP2D6 star-allele haplotype 
 
These polymorphisms can affect CYP2D6 enzyme expression and activity. For 
example, individuals with CYP2D6*1/*10 and CYP2D6*10/*10 genotypes had 3-
fold lower CYP2D6 protein in their liver microsomes when compared to 
CYP2D6*1/*1 individuals (Shimada et al., 2001). Consequently, these 
polymorphisms affect pharmacokinetics, metabolism, safety and efficacy of CYP2D6 
substrate drugs. Based on the CYP2D6 allelic make up, an individual can be classified 
into different categories such as ultra rapid (UM), extensive (EM), intermediate (IM) 
or poor (PM) metabolizer. 
There are considerable differences in the frequencies of CYP2D6 gene 
polymorphisms in different ethnic populations. For example, CYP2D6*4, 
CYP2D6*3, CYP2D6*5 and CYP2D6*6 are present at a combined frequency of 20-
30% in Caucasians (Bradford et al., 2002 and Sistonen et al., 2007) and are the 
primary cause of poor metabolism in this population. However, in Asians and 
Africans, CYP2D6*3-*6 alleles are present in less than 7% frequency (Bradford et 
al., 2002). In Asians, the primary cause for reduced enzyme activity is CYP2D6*10, 
an intermediate metabolizer allele that is present at a frequency of 40-60% (Veiga et 
al., 2009). However, in both Caucasians and Africans, CYP2D6*10 is present at a 
frequency of less than 5% (Bradford et al., 2002). In Africans, the primary cause of 
Chapter 2                    Review of Literature 
26 
reduced enzyme activity are CYP2D6*17 and CYP2D6*29. Both these alleles are 
present in less than 3% frequency in both Caucasian and African populations 
(Bradford et al., 2002 and Sistonen et al., 2007). 
The role of CYP2D6 in cancer susceptibility was explored in earlier works, and there 
are controversial findings for the poor metabolizer (PM) allele frequency and the risk 
of acute lymphoblastic leukemia (Lemos et al., 1999 and Krajinovic et al., 1999). 
Some of them support the assertion that the PM and/or High efficient metabolizer 
(HEM) allele carriers are at increased risk for ALL because of insufficient 
detoxification (Roddam et al., 2000). 
The CYP2D6 gene polymorphism, due to single nucleotide polymorphisms, gene 
duplication and deletion are relatively well known. At least 60 CYP2D6 alleles are 
responsible for the about 200-fold variability in the metabolism. CYP2D6*3 and 
CYP2D6*4 are the most common nonfunctional CYP2D6 alleles in Caucasians 
population. The mutation in CYP2D6*3 consist of a single base-pair deletion in exon 
5 and in the case of CYP2D6*4 in G to A transition in 1934 position which causes an 
altered reading frame shift and a premature stop codon. The carriers of deficient 
(CYP2D6*3/*4) or nonfunctional (CYP2D6*4/*4) alleles are poor metabolizers 
(PM). The homozygote for wild-type CYP2D6 alleles (CYP2D6*1/*1) belong to 
extensive metabolizers (EM), while heterozygous persons to intermediate 
metabolizers (IM). Another relatively common phenomenon in humans is the 
duplication or amplification of CYP2D6. The mechanism involved in the gene 
duplication process is likely to be due to an unequal crossover between the two sister 
chromatides which causes deletion of the CYP2D6 gene (CYP2D6*5) in one 
chromatid and duplication of the gene in the other one (CYP2D6*X2). The presence 
of multiduplicated genes is attributable to additional unequal crossover events 
affecting chromatids that already contain duplicated genes. The carriers of three or 
more active alleles are ultra rapid metabolizers (UM). The clinical relevance of 
genetic polymorphism can be seen in the wide inter individual variability of 
therapeutic efficacy and in the spectrum of drug adverse effects (Agundez et al., 
2001; Daly et al., 1996 and Sachse et al., 1997). 
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2.6 HUMAN CYTOCHROME P4501A1 
Cytochrome P450, family 1, subfamily A, polypeptide 1 is a protein (Kawajiri et al., 
1999) that in humans is encoded by the CYP1A1 gene (Nelson et al., 2004).The 
protein is a member of the cytochrome P450 superfamily of enzymes (Smith et al., 
1998). CYP1A1 is involved in the activation of PAHs into reactive epoxide 
metabolites and it also hydroxylates the two major estrogens, E2 and E1, 
predominantly at the C-2 position (Shimada et al., 2004 and Spink et al., 1992).  
The CYP1A1 (P1-450) gene, located at 15q22-q24, comprises seven exons 1and six 
introns and spans 5810 base pairs (Jaiswal et al., 1985 and Kawajiri et al., 1986). 
Human CYP1A1 (EC: 1.14.14.1) is mainly present in the skin, lungs, placenta, and 
lymphocytes and plays an important role in the metabolic activation of chemical 
carcinogens. Basal CYP1A1 protein expression in all tissues is thought to be low 
(Nebert et al. 2004), but varying levels of CYP1A1 mRNA have been detected 
following induction by polycyclic aromatic hydrocarbons (PAH’s). However, in 
breast tissue, the expression level of CYP1A1 mRNA has been shown to be much 
weaker than that of CYP1B1 mRNA (Hellmold et al., 1998 and Iscan et al., 2001). 
Induction of CYP1A1 gene is regulated by the aromatic (aryl) hydrocarbon receptors 
(AhR) and the AhR nuclear translocator (Whitlock et al., 1999). CYP1A1 is capable 
of oxidizing benzo[a]pyrene and other PAH’s to carcinogenic species (Chun et al., 
1996; Chua et al., 2000; Liu et al., 2003 and Sparfel et al., 2004). This enzyme is 
strongly induced by cigarette smoke and potentially associated with lung cancer 
(Patterson et al., 2002 and Spivack et al., 2003). Like many other P450s, CYP1A1 is 
polymorphic and genetic variation is thought to play a role in determining cancer 
susceptibility (Miyoshi et al., 2002; Han et al., 2003 and Balasubramanian et al., 
2004). 
 
Fig: 2.7: Representative structure of CYP1A1 gene 
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CYP1A1 GENE POLYMORPHISMS 
Several polymorphisms have been identified in CYP1A1 gene. Some of which lead to 
more highly inducible Aryl hydrocarbon hydroxylase (AHH) activity.CYP1A1 
polymorphisms include:  
 M1, T→C substitution at nucleotide 3801 in the 3'- non-coding region 
 M2, A→G substitution at nucleotide 2455 leading to an amino acid change 
of isoleucine to valine at codon 462 
 M3, T→C substitution at nucleotide 3205 in the 3'- non-coding region 
 M4, C→A substitution at nucleotide 2453 leading to an amino acid change 
of threonine to asparagine at codon 461 (Petersen et al., 1991; Cosma et al., 
1993 and Crofts et al., 1996) 
Several polymorphic sites for the CYP1A1 have been reported. The first reported 
CYP1A1 polymorphism (T3801C) was detected by the MspI restriction enzyme 
(Spurr et al., 1987). This polymorphic site is located in the 3’ non coding region of 
CYP1A1 and results in CYP1A1*2A allele. In African and Americans, an additional 
MspI restriction site exists in the 3’ non-coding region (T3205C) resulting in 
CYP1A1*3 allele, but this has not been reported among Caucasians or Asians (Crofts 
et al., 1993). Two polymorphisms in exon 7 result in amino acid changes at codons 
461 (Thr→Asn) and 462 (Ile→Val), which are situated near the catalytic region of the 
CYP1A1 (Crofts et al., 1994 and Cascorbi et al., 1996). These alleles are named 
CYP1A1*4 and CYP1A1*2C, respectively. Even though they are situated in adjacent 
codons, they are not linked with each other (Cascorbi et al., 1996). Instead, strict 
linkage between the T3801C and Ile 462 Val polymorphisms has been observed 
among Caucasians (Cascorbi et al., 1996; Hirvonen et al., 1992 and Fontana et al., 
1998). 
Polymorphism of CYP1A1 and exposure to chemicals such as polyaromatic 
hydrocarbons (PAHs) in relation to cancer may be given as an example for xenobiotic 
metabolizing enyzmes polymorphisms, chemical exposure and cancer susceptibility. 
Studies were carried out to demonstrate the association between CYP1A1 
polymorphisms and smoking related cancers. CYP1A1 polymorphisms were found to 
be associated with lung (Coles et al., 1990 and McClellan et al., 1996), head and 
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neck (Doll et al., 1998), prostate (Murata et al., 2001) and colorectal (Sivaraman et 
al., 1994) cancers. Benzo(a)pyrene (BaP) found in the tobacco smoke, is one of the 
substrate of CYP1A1. Within body, BaP is converted to BaP 7, 8 diydrodiol‐ 9, 
10‐epoxide (BPDE) by several reactions of CYP family. BPDE is one of the most 
carcinogenic compound ever known by CYP1A1, which can bind to DNA and forms 
DNA‐adducts (Parke et al., 1991). Interestingly, CYP1A1 is induced by BaP itself, 
which causes higher rate of CYP1A1 expression and so higher activity of CYP1A1 
enzyme and increased rate of accumulation of carcinogenic compound (Stegeman et 
al., 1995 and Arınç et al., 2000).  
The polymorphism of CYP1A1 and its association with childhood ALL were studied 
by several groups. Previous association studies have shown that variants within 
cytochrome P4501A1 (CYP1A1), a member of the CYP1 gene family of constitutive 
and inducible enzymes with a major role in the oxidative activation and/or 
deactivation of a wide range of xenobiotics, are associated with increased risk in ALL 
(Krajinovic et al., 1999; Sinnett et al., 2000; Krajinovic et al., 2001 and Canalle et 
al., 2004). In particular, two common polymorphisms in the CYP1A1 gene, a T6235C 
change within the 3′ noncoding region of the gene (*2A, also known as the MspI 
restriction fragment length polymorphism) and an A4889G change in the heme-
binding domain of exon 7 (*2C), have been previously described to influence 
enzymatic activity (Hayashi et al., 1991). An elevation in CYP1A1 enzyme activity 
has been found with the A4889 polymorphism in exon 7 alone and when combined 
with the T6235C polymorphism to form the CYP1A1*2B genotype (Crofts et al., 
1994). CYP1A1 polymorphisms have been found to be significantly associated with 
both an increased genetic susceptibility (Krajinovic et al., 1999) and its worse 
prognosis (Krajinovic et al., 2002) for childhood ALL among French–Canadians. 
Another study found that CYP1A1 polymorphisms greatly increased susceptibility of 
ALL among Indian children with the homozygous CYP1A1*2A conferring a 6-fold 
risk and the CYP1A1*2C conferring a 4-fold risk (Joseph et al., 2004). However, a 
possible role of CYP1A1 polymorphisms in ALL was not confirmed in Turkish 
(Balta et al., 2003; Aydin-Sayitoglu et al., 2006), Brazilian (Canalle et al., 2004) or 
Chinese (Chen et al., 2008) study groups.  
Although research has elucidated tumorigenic characteristics of CYP1A1 
polymorphisms, these studies have not examined the impact of ethnicity on these 
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variants and ALL risk. No study has investigated the importance of CYP1A1 
polymorphisms and ethnic status by comparing Caucasian, Hispanic, and African-
American children. Furthermore, no studies have explained the increased incidence of 
ALL in the U.S. Hispanic population. 
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3.1  MATERIAL 
3.1.1 STUDY POPULATION 
Subjects were recruited at Sher-i- Kashmir Institute of Medical Science (SKIMS), 
Srinagar Kashmir. The recruitment process was initiated following approval from the 
ethical committee of SKIMS. The diagnosis of Acute lymphoblastic leukemia (ALL) 
was based on the standard histopathological criteria. Controls were taken from healthy 
individuals of Kashmir valley from Department of Hematology, SKIMS, Soura, 
following the referral pattern of sex and age matched patients. None of the controls 
had a personal history of malignancy. 
3.1.1.1 SUBJECTS 
Criteria adopted for selecting the cases and controls 
The criteria for including or excluding a subject in the study were formulated prior to 
the commencement of the study. 
Cases 
All the documented confirmed ALL patients were included irrespective of cancer 
stage but were age and gender matched.  
Exclusion criteria 
Under the following conditions the patients were not recruited in the study; 
 Patients suffering from any disease that affected their life style. 
 Patients who had received prior chemo or radiotherapy. 
 Patients not belonging to Kashmir valley. 
 Who did not agree to participate 
Inclusion Criteria 
 Documented proven ALL patients. 
 Patients who were willing to take part in the study 
 Patients below the age of 20 years were included. 
 Patients belonging to Kashmir valley 
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Controls 
Controls were matched with the cases by age and gender. 
Exclusion criteria 
 Patients who ever suffered from any kind of malignancy. 
 Patients who did not agree to participate. 
Inclusion criteria 
 Residents of the Kashmir valley. 
 Matched male and female ratio with the cases. 
3.1.2   COLLECTION OF BLOOD SAMPLES 
Individuals who gave consent to participate in this case-control study were included in 
the study. Blood samples were collected from both cases and the controls. Around 
three milliliter (3 ml) of peripheral blood was collected from each subject in sterilized 
plastic vials containing EDTA (0.5M; pH-8.0) and stored at -20
o
C for further analysis. 
3.2 METHODS 
3.2.1    DNA EXTRACTION FROM WHOLE BLOOD 
Blood samples of about 2 ml were obtained from the patients in the EDTA coated 
plastic vials and genomic DNA was isolated by Phenol-chloroform method as per the 
given procedure (Sambrook and Rusell, 2001). 
1. Cells were first lysed with 4ml of freshly prepared Lysis buffer (155mM 
NH4Cl, 10 mM KHCO3 and 0.1 mM EDTA) with gentle mixing and kept at 
- 20
o
C for 15 minutes. 
2. The tubes were then centrifuged at 8000 rpm for 10 minute and then 
supernatant   was discarded. 
3. The pellets were resuspended in 2 ml of SE, 100μg/ml Proteinase k 
(100µg/ml) and 200 µl of 10% SDS. The solution were then incubated at 
37
o
C overnight. 
4. On the next day, equal volumes of Tris-saturated-phenol (pH 8) were added   
to the samples and mixed thoroughly by inverting the tube for 15-20 
minutes. 
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5. The tubes were then centrifuged at 6000 rpm for 10 minutes. The aqueous     
supernatants were transferred to fresh tubes and to it, an equal volume of 
phenol-CIA (chloroform-isoamyl alcohol) were added. 
6. The tubes were shaken gently for 15 minutes and then centrifuged at 7000 
rpm for 10 minutes. 
7. The supernatant formed were transferred to fresh tubes and an equal volume 
of CIA was added to them. 
8. The tubes were again shaken gently for 15-20 minutes and then centrifuged 
at 8000 rpm for 10 minutes. 
9. To the supernatant, an equal volume of chilled ethanol and 0.1   volume of 
sodium acetate was added to precipitate the DNA immediately. 
10. After retrieving, the DNA was washed thrice with 70% ethanol and 
subsequently dissolved in 5 ml of DNA storage buffer and stored at 4oC for 
future use. 
3.2.2 DETERMINATION OF CONCENTRATION, PURITY AND QUALITY   
OF GENOMIC DNA           
3.2.2. Qualitative Analysis 
The quality of the genomic DNA was assessed on 0.8% gel electrophoresis. 2μl of 
each DNA sample was mixed with 1μl of 1X DNA loading dye (1X loading dye 
consisted of 4.16 mg bromophenol blue, 4.16 mg xylene cyanol and 0.66g sucrose in 
1ml water) and was loaded in the gel. The voltage was kept constant at 20V until 
DNA left the wells and moved into the gel,for rest of the run voltage was raised to 
50V. Run was stopped when the dye had travelled nearly 2/3rd of the gel. Gel was 
visualized by a Gel doc system (Alphaimager
TM
 2200, Alpha InfoTech Corporation) 
under UV light and picture was captured by using CCD camera system. 
3.2.2.2   Quantitative Analysis 
The quantity of the DNA was estimated by making appropriate dilutions to determine 
the optical density (OD) at 260 nm and 280 nm by double beam spectrophotometer 
(Spectron 2206) and the concentration was determined using equation: 
DNA (μg/ml) = A260 x 50 x dilution factor 
The ratio of A260/A280 was calculated and the DNA samples for which the ratio was 
1.7-1.9 were considered for the future use. The DNA was stored at 4
o
C for a short 
time but the stock was kept at -20
o
C for further use. 
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3.2.3   AGAROSE GEL ELECTROPHORESIS  
 The edges of clean, dry glass plates were sealed with tape to form a mold, and 
were set on a horizontal section of the bench. 
 Sufficient electrophoresis buffer (1xTAE) was prepared to cast the gel and to 
fill the electrophoresis tank. 
 0.8g of agarose was dissolved in 100 ml of 1xTAE buffer and heated in an 
oven until a clear transparent solution formed. 
 After removing from the oven the solution was allowed to cool to 50-60oC and 
then few (5μl) of ethidium bromide was added as visualizing agent. 
 The warm agarose was poured into the mold. An appropriate comb was 
positioned for forming the sample slots in the gel when the agarose was added 
to the mold. 
 The gel was allowed to set completely (30-45 min), then a small amount of 
TAE buffer was poured on top of the gel and comb was carefully 
removed.TAE buffer was poured, after removing tape also, and gel was 
mounted in the tank. 
 Sample was mixed with few (2-3 μl) of 6Χ gel loading buffer. 
 Sample was loaded slowly and carefully into the slot of submerged gel using 
disposable loading tips. 
 Lid of gel tank was closed and electric leads connected. DNA migrated toward 
positive anode. Voltage of 1-5 V/cm was applied (distance measured from 
cathode to anode). The gel was allowed to run until the bromophenol blue and 
xylene cyanol migrated an appropriate distance through the gel. 
Pattern of separation was visualized by a Gel doc system (Alphaimager
TM
 
2200, Alpha InfoTech Corporation) under UV light and picture was captured 
by using CCD camera system. Samples containing high molecular weight 
DNA with no fragmentation/ shearing and without any apparent contamination 
or streaking were selected for further analysis. 
3.2.4 GENOTYPING OF CYP2D6 AND CYP1A1 GENES 
Once it was confirmed that the genomic DNA is present, the concentration and purity 
is also desirable, the two xenobiotic metabolizing enzyme genes: CYP2D6 and 
CYP1A1 were genotyped for their most common single nucleotide polymorphisms.  
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CYP2D6 (G1934A) and CYP1A1 (T6235C) polymorphisms were identified by PCR 
amplification of SNP regions. The standard protocol for PCR was used, however the 
technique was standardized and optimized for available laboratory conditions. After 
standardizing all the parameters of the technique like varying annealing temperature 
from 56
o
C to 64
o
C (CYP2D6 gene) and 55
o
C to 65
o
C (CYP1A1 gene), dNTPs, primer 
and template concentration, the 5' UTR of these genes were amplified. PCR was 
performed in a total volume of 25μl for both genes. For these two genes, the PCR 
reactions composed of 50-150 ng genomic DNA, 0.2mM dNTPs, 0.4pmoles/μl of 
each primer and 1.5 U of Taq polymerase in 1X PCR buffer were used. Lyophilized 
primer stocks were diluted first to 100pmol/μl concentration and then to 20pmol/μl 
using mili Q water. PCR buffer contained Tris-Cl, KCl, (NH4)2SO4 and 15mM MgCl2 
(pH 8.7). Amplification and specificity of amplicon obtained in the PCR reaction was 
analyzed by agarose gel electrophoresis on 2.5% gel. After the electrophoresis, the gel 
was visualized using UV-illuminator and photographed in a Gel Doc (Alphaimager
TM
 
2200, Alpha InfoTech Corporation ). 
3.2.4.1 Genotyping of CYP2D6 G1934A Polymorphism: 
In this study, CYP2D6 gene was genotyped by PCR for the detection of CYP2D6 
(G1934A) (Arg281His) polymorphism. G1934A mutation is located between the 
junction of intron 3 and exon 4 region of the gene. A 334bp fragment covering 
G1934A point mutation was amplified. The primer pair used for amplification was: 
 
 
                                                 
CYP2D6 
                                          
 
 
 
 
Forward primer: 5’- GCCTTCGCCAACCACTCCG-3’ 
 
Reverse primer: 5’- AAATCCTGCTCTTCCGAGGC-3’ 
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Table 3.1: Volume of different reagents used in 25µl of PCR of CYP2D6 gene 
Reagent Volume used 
10X PCR reaction buffer 2.5 µl 
MgCl2 2.1 µl 
dNTP mix 0.7 µl 
Forward Primer  0.45 µl 
Reverse Primer 0.45 µl 
Genomic DNA 1.5 µl 
Taq DNA polymerase  0.3 µl 
Milli Q water  17 µl 
Total Volume 25.0 µl 
 
PCR Amplification 
Reaction mixture in PCR tubes was gently mixed and placed in a twenty-five well 
automated thermal cycler (Eppendorf). The different temperatures were set as given in 
the Table-3.2. During this procedure precautions were taken to keep the Taq 
polymerase active by not only preparing the reaction under 4
o
C temperature but also 
adding the various reaction components as quickly as possible. The PCR conditions 
were selected after extensively standardizing all the PCR parameters. 
Table 3.2: PCR cycling parameters for CYP2D6 Gene 
Steps Temperature 
o
C Time 
Initial Denaturation 
 
95 
 
5 minutes 
 
Denaturation 
 
95 
 
59 seconds 
Annealing 
 
59.7 
 
59 seconds  33 Cycles  
Extension 
 
72 
 
59 seconds 
Final extension 
72 
 
10 minutes 
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3.2.4.2 Genotyping of CYP1A1 T6235C polymorphism: 
CYP1A1 gene was genotyped by PCR method for the detection of CYP1A1 T6235C 
polymorphism located 264bp downstream from the 3’-flanking region, forming an 
Msp1 restriction site (CYP1A1m1). A 899bp fragment covering T6235C point 
mutation was amplified. The primer pair used for amplification was;              
 
                               
CYP1A1 
                               
 
Table 3.3: Volume of different reagents used in 25µl of PCR of CYP1A1 gene 
Reagent Volume used 
10X PCR reaction buffer 2.5 µl 
MgCl2 1.8 µl 
dNTP mix 0.7 µl 
Forward Primer  0.6 µl 
Reverse Primer 0.6 µl 
Genomic DNA 2.0 µl 
Taq DNA polymerase  0.3 µl 
Milli Q water  16.5 µl 
Total Volume 25.0 µl 
 
 
 
 
Forward primer: 5’- GGCTGAGCAATCTGACCCTA-3’ 
 
Reverse primer: 5’- TAGGAGTCTTGTCTCATGCCT-3’ 
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Table 3.4: PCR cycling parameters for CYP1A1 Gene 
Steps Temperature 
o
C Time 
Initial Denaturation 95 5 minutes 
Denaturation 95 59 seconds 
Annealing 63 50 seconds     33 Cycles 
Extension 72 59 seconds 
Final extension 72 10 minutes 
 
3.2.5 Purification and DNA Sequencing  
The purification and sequencing was done commercially by using the services of Sci-
Genomics, Kerala. For purification and sequencing, 50 µl of unpurified PCR product 
samples along with 50µl of 20µM Forward & Reverse primers were used. DNA 
sequences of the amplicons were obtained in pdf formats. The pdf file of each DNA 
sequence was used for visual inspection of the sequencing chromatograph using 
Acrobat Reader 5.0.  
3.2.6. Statistical Analysis  
The allele frequency for each allele was determined by gene counting. The allele and 
genotype frequencies of patients were given together with the 95% confidence 
interval (CI). Statistical analyses were conducted using software Graph Pad Prism 
version 5.0. The genotype distributions of polymorphisms were compared by χ2 – test 
(Pearson). A p value <0.05 was considered to be statistically significant throughout 
the population comparison. Comparisons of genotypes in control and ALL patient 
groups were done by calculation odds ratios (OR).  
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4.1 GENERAL CHARACTERISTICS OF STUDY POPULATION 
In the present study 120 blood samples from ALL patients and 110 blood samples 
from healthy controls were analyzed. General characteristics of the ALL patients and 
controls are given in table 4.1. 
Table 4.1:  General characteristics of the study population 
 
Characteristics 
Cases 
n=120 (%) 
Controls 
n=110 (%) 
P value* 
Mean Age   (±SD) 
 
>10 
<10 
 
 
55 (45.83) 
65(54.16) 
 
 
47(42.72) 
63(57.27) 
 
0.73 
Gender 
Male 
Female 
 
70(58.33) 
50( 41.66)    
     
 
62(56.36) 
48(43.63) 
0.86 
Dwelling 
Rural 
Urban 
 
    110 (91.67) 
  10 (8.33) 
 
96 (87.27) 
14 (12.73) 
0.38 
Occupation 
Un-employed 
Employed 
 
   95 (79.17) 
   25 (20.83) 
 
80 (72.73) 
30 (27.27) 0.32 
 
n =No. of individuals 
Values represent ±S 
*p using χ2 Test (p<0.05, Data statistically significant) 
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4.2      EVALUATION OF DNA CONCENTRATION AND PURITY 
The genomic DNA was extracted from the whole blood samples from the ALL 
patients and controls of Kashmir. The integrity, concentration and purification of the 
genomic DNA was checked not only by UV-spectrophotometer but also by agarose 
gel electrophoresis, by analyzing 3-4 μl of genomic DNA on the 0.8 % agarose gel 
(Fig.4.1), which reflected the intactness of genomic DNA, because the genomic DNA 
was restricted to the wells with no smear in the gel suggesting that DNA was not 
degraded. The results showed that DNA concentration of the samples ranged from 
300ng/μl to 1200 ng/μl which was sufficient enough to carry out the other phases of 
the study. The purity of DNA was determined by A260 / A280 ratio and it was found 
that the ratio in all DNA preparations was in the range of 1.60-1.94.Agarose gel 
electrophoresis also demonstrated that DNA samples had high molecular weight 
without degradation. Fig. 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4                    Results 
                                                                                        41 
 
 
 
 
Lane:      
   1          2         3         4          5          6          7         8 
 
Fig 4.1: Representative gel picture showing the integrity of genomic 
DNA on 0.8% agarose gel. Lane 1-8 represents intact genomic DNA 
extracted from some cases. 
 
 
 
 
 
 
 
 
 
 
Genomic DNA 
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Lane:  
   1         2         3         4          5          6         7         8 
 
Fig 4.2: Representative gel picture showing amplification of exon 4 
of CYP2D6 gene on 2.5% Agarose gel of some ALL samples. Lane 
no.5 represents 100bp ladder, lane no. 1, 2, 3, 4, 6, 7 and 8 
represents 334bp fragment of CYP2D6 amplified PCR product 
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4.3 ANALYSIS OF CYP2D6*4 (G1934A) POLYMORPHISM  
CYP2D6*4 (G→A transition at position 1934) polymorphism was analyzed through 
RFLP method, already described in the methodology section. Subsequently after 
amplification, PCR products were subjected to restriction digestion using BstN1 
enzyme (New England Biolabs, USA). The samples were genotyped on 3% agarose 
gel. The normal allele i.e homozygous individuals G/G, of CYP2D6*4 polymorphism 
produces two fragments of size 230bp and 104bp after digestion with BstN1 
restriction enzyme. Heterozygotes (G/A) produced three fragments of 334bp, 230bp 
and 104bp. G to A transition at position 1934 abolishes the restriction site and a 
fragment of 334 bp was observed in mutant allele (i.e A/A) as shown in Fig 4.3. 
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Lane: 
1         2        3         4         5         6        7        8 
 
Fig 4.3: Representative gel picture showing restriction digestion 
pattern of amplified exon 4 of CYP2D6 gene on 3% Agarose gel 
electrophoresis of some ALL cases. Lane 4 represents DNA 
marker; lane 1, 3, 5, 6 & 7 represents the homozygous condition 
(G/G); lane 8 represents the heterozygous condition (G/A); 
whereas lane 2 represents the homozygous mutant condition (A/A). 
 
 
 
 
 
 
 
 
 
 
334bp 
230bp 
104bp 
100bp 
ladder 
200bp 
300bp 
Chapter 4                    Results 
                                                                                        45 
 
 
Fig 4.4:  Representative chromatogram of direct sequencing for CYP2D6 gene in 
controls. 
 
 
Fig 4.5: Representative chromatogram of direct sequencing for CYP2D6 gene in 
ALL patients 
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Fig 4.6: Representative chromatogram of direct sequencing for CYP2D6 unaffected 
individuals. The CYP2D6 of unaffected individuals contains a “G nucleotide base 
at 1934 position 
 
                                                                                       
 
Fig 4.7: Representative chromatogram of direct sequencing for CYP2D6 affected 
individuals. The CYP2D6 of affected individuals contains a G      A transition at 
1934 position. 
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Table 4.2: Genotypic Frequencies of CYP2D6 in ALL patients and controls 
Gene Genotypes 
Cases 
n = 120 
(%) 
Control 
n = 110 
(%) 
OR (95% CI) P* value 
CYP2D6 
 
Wild (G/G) 
 
40  
(33.33) 
 
106 
(96.36) 
 
1 
 
- 
 
Referent 
 
Hetero(G/A) 
 
28  
(23.33) 
 
2  
(1.82) 
 
37.10 
 
8.44 – 163 
 
< 0.0001 
 
Mutant(A/A) 
 
52  
(43.33) 
 
2  
(1.82) 
 
68.90 
 
16.02 - 296.3 
 
< 0.0001 
 
*P using χ2 test 
p<0.05 (Data statistically significant) 
 
 
 
Table 4.3: Allelic frequency of CYP2D6 in ALL patients and controls 
Polymorphism Alleles 
Cases 
n
s
 (%) 
240 
Control 
n
s
 (%) 
220 
OR (95% CI) P* Value 
CYP2D6*4 
1934G>A 
 
G 
 
108  
(45.0) 
 
214  
(97.27) 
 
1 
 
- 
 
Referent 
A  
132  
(55.0) 
 
6  
(2.72) 
 
43.59 
 
18.62 - 102.0 
 
< 0.0001 
 
n
s
=No. of Alleles 
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Fig 4.8: Histogram showing the genotype distribution in ALL 
patient and controls of Wild genotype (G/G) 
 
 
Fig 4.9: Histogram showing the genotype distribution in ALL 
patients and controls of Hetero genotype (G/A). 
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Fig 4.10: Histogram showing the genotype distribution in ALL 
patients and controls of Mutant genotype (A/A). 
 
 
Fig 4.11: Histogram showing the allele distribution of CYP2D6 
in ALL patients and controls. 
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Lane: 
   1         2        3         4         5         6         7        8 
                    
 
Fig 4.12: Representative gel picture showing amplification of 
899bp of 3’ non coding region of CYP1A1 gene on 1.5% Agarose 
gel of some ALL cases. Lane no.1 represents 100bp ladder, lane 
no. 2, 3, 4, 5, 6, 7 and 8 represents amplified PCR product. 
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4.4 ANALYSIS OF CYP1A1*2A T6235C (m1) POLYMORPHISM 
3’UTR of CYP1A1*2A mutation of T6235C transition (m1, T→C transition at 
position 6235) were characterized by the PCR-RFLP approach as already described in 
the methodology section. PCR products so obtained were subjected for restriction 
digestion using Msp1 (New England Biolabs, Schwalbach, Germany). The samples 
were genotyped on 2% agarose gel. It was observed that the homozygous individuals 
(T/T) produced one band corresponding to 899 bp. Heterozygotes (T/C) produced 
three fragments corresponding to 899, 693 and 206 bp and homozygotes mutants 
(C/C) produced two bands which correspond to 693 and 206 bp fragments after 
digestion, as m1 T→C transition at position 6235 in CYP1A1 gene create the 
restriction site which results in smaller fragments of 693 and 206bp. Fig. 4.13 
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Lane: 
    1         2          3         4          5          6         7          8 
 
Fig 4.13: Representative gel picture showing restriction digestion 
pattern of the amplified product of 3’ non coding region of CYP1A1 
gene on 2% Agarose gel of some ALL cases. Lane 4 represents 
DNA marker; lane 2, 3, 5 & 8 represents the homozygous condition 
(T/T); lane 1 & 7 represents the heterozygous condition (T/C); 
whereas lane 6 represents the homozygous mutant condition (C/C). 
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Fig 4.14: Representative chromatogram of direct sequencing for CYP1A1 gene in 
controls. 
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4.15: Representative chromatogram of direct sequencing for CYP1A1 gene in ALL 
patients. 
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Fig 4.16: Representative chromatogram of Direct sequencing for CYP1A1 
unaffected individuals. The CYP1A1 of unaffected individuals contains a “T” 
nucleotide base at 6234 position.  
 
 
                                      
 
 
 
 Fig 4.17: Representative chromatogram of direct sequencing for CYP1A1 affected 
individuals. The CYP1A1 of affected individuals contains T    C transition at 6234 
position. 
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Table 4.4: Genotypic Frequencies of CYP1A1 in ALL patients and controls 
 
Gene Genotypes 
Cases 
n(%) 
120 
Control 
n(%) 
110 
OR (95%CI) P* value 
CYP1A1 
 
Wild (T/T) 
 
85 
(70.83) 
 
94 
(85.45) 
 
1 
 
- 
 
Referent 
 
Hetero(T/C) 
 
30 (25) 
 
25 
(22.73) 
 
1.33 
 
0.72 - 2.43 
 
0.44 
 
Mutant(C/C) 
 
5 (4.17) 
 
1 (0.91) 
 
5.53 
 
0.63 - 48.31 
 
0.19 
 
 
*P using χ2 test 
p˃0.05 (Data statistically insignificant) 
 
 
 
Table 4.5 The distribution of CYP1A1 alleles in ALL patients and control 
 
Polymorphism Alleles 
Cases 
n
s
 (%) 
240 
Control 
n
s
 (%) 
240 
OR (95% CI) P* Value 
CYP1A1*2A 
6235T>C 
 
T 
 
200 
(83.33) 
 
213 
(88.75) 
 
1 
 
- 
 
Referent 
 
C 
 
40 
(16.66) 
 
27 
(11.25) 
 
1.57 
 
0.93 - 2.66 
 
0.11 
 
n
s
= No. of Alleles  
 
 
 
 
 
Chapter 4                    Results 
                                                                                        57 
 
 
 
Fig 4.18: Histogram showing the genotype distribution in 
ALL patients and controls of Wild genotype (T/T). 
 
 
 
Fig 4.19: Histogram showing the genotype distribution in 
ALL patients and controls of Wild genotype (T/C). 
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Fig 4.20: Histogram showing the genotype distribution in 
ALL patients and controls of Mutant genotype (C/C). 
 
 
 
 Fig 4.21: Histogram showing the allele distribution of CYP1A1 
in ALL patients and controls. 
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cute lymphoblastic leukemia (ALL) accounts for approximately 74% of the 
leukemia cases among children in between the age group of 0 to 19 years old 
and an estimated 5,300 cases were diagnosed in 2010 in the United States. Despite, 
80% of overall 5-year survival, ALL remains a major cause of childhood mortality 
(SEER, 2011; American Cancer Society, 2011 and McNeil et al., 2002). There is 
significant ethnic variation in incidence rates with Hispanics having the highest rate 
(44/million), followed by Whites (36/million) and African Americans with the lowest 
rate (20/million) (SEER, 2011). The etiology of childhood leukemia continue to be 
incompletely explained but have been linked to environmental exposures and multiple 
low penetrance of genetic factors (McNeil et al., 2002 and Bolufer et al., 2006). 
Studies of childhood leukemia have suggested that genetic variants within xenobiotic 
metabolizing enzymes (XMEs) significantly affect susceptibility to childhood ALL 
(Sinnett et al., 2000; McNeil et al., 2002; Canalle et al., 2004 and Buffler et al., 
2005) and that XME polymorphisms may be significant predictors of chemotherapy 
response and survival for children suffering from leukemia (Krajinovic et al., 1999; 
McNeil et al., 2002; Canalle et al., 2004 and Buffler et al., 2005). Genetic 
susceptibility to leukemias can be related to the polymorphisms in CYP2D6 and 
CYP1A1 genes and consistent with this paradigm several polymorphisms have been 
identified in the pathogenesis of lymphoid malignancies. Cytochrome P450 2D6 
(CYP2D6) and Cytochrome P4501A1 (CYP1A1), the member of the cytochrome P450 
mixed-function oxidase system, are the most important enzymes involved in the 
metabolism of various drugs in the body. Also, many drugs are activated by CYP2D6 
and CYP1A1 to form their active compounds. While CYP2D6 is involved in the 
oxidation of a wide range of substrates. There is considerable variability in its 
expression in the liver, while as CYP1A1 is involved in the metabolic activation of 
aromatic hydrocarbons (polycyclic aromatic hydrocarbons). These genes are highly 
polymorphic in the population; certain alleles result in the poor metabolizer 
phenotype, characterized by a decreased ability to metabolize the enzyme's substrates 
and certain result in intermediate metabolizer, characterized by intermediate capacity 
to metabolize the substrate (Krajinovic et al., 2002). However, actual phenotype 
depends on the nature of drug substrate and non-genetic factors, particularly co-
medications. Alternative spliced transcript variants encoding different isoforms have 
A 
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been found for these genes. Taking this information into consideration, it seems 
plausible that inter- individual differences in CYP2D6 activity can produce adverse 
effects or lack of therapeutic effect with an altered risk for cancers (Nageswararao et 
al., 2010). The most common inactivating mutation is the transition G1934A at the 
splice site resulting in truncated protein with no enzymatic activity (Smith et al., 
1995). Also, studies have shown that variants within cytochrome P450 1A1 (CYP1A1), 
a member of the CYP1 gene family of constitutive and inducible enzymes are 
associated with increased risk in ALL (Gough et al., 1990 and Canalle et al., 2004). 
Thus, CYP2D6 and CYP1A1 encodes crucial enzyme in drug metabolism and 
therefore, are good candidates for studying the effect of polymorphisms on drug 
metabolism and their role in development of malignancies. The present study was 
conducted on Kashmiri children to investigate gene polymorphism of CYP2D6 and 
CYP1A1 and their association with ALL. The study was carried out with 120 ALL 
cases 110 controls (age group, sex, region, occupation) by RFLP-PCR analysis. In the 
transition of CYP2D6*4 1934G>A, it was observed that the CYP2D6 (G) allele 
frequency was 97.27% in the controls and 45% (OR=1, CI 95%) in cases and 
CYP2D6 (A) allele frequency was 2.72% in the controls and 55% (OR=43.59, 18.62-
102) in cases. This difference in frequency was found to be statistically significant 
with a P = 0.0001 (p< 0.05).  While as in the transition of CYP1A1*2A 6235T>C, the 
frequency of CYP1A1 (T) allele was 88.75% in the controls and 83.88% (OR=1, CI 
95%) in cases and CYP1A1 (C) allele frequency was 11.25% in controls and 16.66% 
(OR=1.57, CI 95%, 0.93-2.66) in cases. This difference in frequency was found to be 
statistically insignificant with a P= 0.11 (p> 0.05).  The CYP2D6 wild (G/G) 
genotype  (Extensive metabolizer) frequency was found to be present in 33.33% of 
the cases and 96.36% of the controls, the hetero (G/A) variant (Intermediate 
metabolizer)  in 23.33% of the cases and 1.82% of controls, and the mutant (A/A) 
genotype  (Poor metabolizer) in 43.33% of cases and 1.82% of controls. Similarly in 
case of CYP1A1, the wild (T/T) was found to be present in 70.83% of cases and 
85.45% in controls, the hetero (T/C) genotype in 25% of  the cases and 22.73% of 
controls and the mutant (C/C) was found to be present in 4.17% of the cases and 0.9% 
of controls. We observed that an increased risk associated with CYP2D6 Mutant(A/A)  
genotype 43.33% (OR = 68.90, 95% CI, 16.02-296.3;  P = <0.0001 ) and Wild (G/G) 
genotype 33.33% (OR = 1; 95%CI) and  low with hetero (G/A)  genotype 23.33%  of 
CYP2D6 as compared to the controls and also increased risk is associated with 
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CYP1A1 wild (T/T) genotype 70.83 %  (OR 1, CI 95%) and hetero 25%  (OR 1.33, 
95% CI,  0.72- 2.43; P = 0.44) and low in case of mutant (C/C) genotype 4.17% ( OR 
= 5.53, CI 95% 0.63-48.31, P = 0.19) as compared to the controls. We observed that 
in CYP2D6, the incidence of ALL is higher in the children of age group in between 0 
to 5 years in cases and least in the age group of 21 to 25 in cases, when compared to 
the controls (Fig 4.10). Similarly, in case of CYP1A1, the incidence of ALL was 
found to be higher in the children of age group 0 to 5 years in cases as compared to 
controls (Fig. 4.20).  
We also observed that in CYP2D6, although the proportion of patients who were 
homozygous mutant (A/A) was higher in cases than in controls, the difference was not 
statistically significant when using wild (G/G) genotype as a reference (OR= 68.9; 
95% CI, 16.02-296.3; P = < 0.0001). Similarly, we observed the frequency of the 
heterozygous genotype (G/A) when compared with A/A genotype was not much 
different between the cases and controls hence, statistically insignificant (OR=37.1; 
95% CI, 8.44- 163; P = < 0.0001). Similarly, in CYP1A1 we observed that the 
proportion of patients who were homozygous mutant (C/C) was lower in cases and in 
controls, the difference was statistically significant when using wild (T/T) genotype as 
a reference (OR= 5.53; 95% CI, 0.63-48.31; P = 0.19). Similarly, we observed the 
frequency of the heterozygous genotype (T/C) when compared with T/T genotype 
was again lower in cases and controls hence, statistically significant (OR=1.33; 95% 
CI, 0.72-2.43 ; P = 0.44). This finding is in line with the findings of (Krajinovic et 
al., 1999 and Nageswararao et al., 2010) and other studies. Therefore, the 
polymorphism CYP2D6 needs to be evaluated in detail to conclude its role on the 
development of acute lymphoblastic leukemia in Kashmiri population. On the basis of 
results, our study suggests that there is an association between gene polymorphism of 
CYP2D6 and CYP1A1 and the development of ALL in Kashmiri children. However 
these findings need to be substantiated with larger sample size to clarify the real 
contribution of these genes in the susceptibility to ALL in different world populations.  
The reasons for contrary results obtained from several studies remain ambiguous and 
might be attributed to differences in ethnic backgrounds and the selection of the 
population studied, differences in sample sizes, and gene-environment interactions, 
such as diet, exposure to chemicals and nutritional intake. Furthermore, inherited 
biases accompanied with hospital based case –control studies may also be attributed 
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to spurious findings or false positive results. Due to limited studies reporting the 
influence of gene polymorphism involved in drug metabolism on ALL, more 
investigations are necessary to find a clear relationship of these genes to susceptibility 
to ALL. 
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Chemicals and other miscellaneous items 
The details of chemicals and other miscellaneous items used in the study 
Chemicals/Enzymes      Source 
Proteinase k                              Sigma 
Chloroform                             Qualigens 
Isoamyl alcohol                          Qualigens 
EDTA-disodium     CDH 
SDS                     Sigma 
Tris-HCl                             Himedia 
Magnesium chloride        Sisco Research Lab 
Ethanol                                        Jiangsu Huaxi International Co.Ltd 
Phenol                                                     Qualigens 
Sodium acetate                                       S.D. fine chem.pvt ltd 
Ethidium bromide                                        Himedia 
Bromophenol blue                                         Himedia 
Tris – base                                       Himedia 
Acetic acid                            Qualigens 
Sucrose                                                        Sisco Research Lab 
Sodium hydroxide                         RANKIN 
Sodium chloride                           Sisco Research Lab.Pvt.Ltd 
Agarose low EEO                         Sisco Research Lab.Pvt.Ltd 
Isopropanol                                  Qualigens 
Ammonium chloride                  D.D. Fine Chem.Pvt.Ltd 
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Taq DNA polymerase                       GENETAQ
TM
 
dNTPs                                       Sigma Aldrich 
100bp Ladder                                         Sigma Aldrich 
Oligonucleotides               Sigma Aldrich 
REAGENTS 
REAGENTS FOR DNA EXTRACTION 
Chloroform isoamyl alcohol (CIA) 
Chloroform       24.0 ml 
Isoamyl alcohol                            1.0 ml 
Chloroform: isoamyl alcohol, in the ratio 24:1 was prepared by mixing 24 ml of 
Chloroform and 1 ml of isoamyl alcohol. The solution was stored at 4˚C in dark 
bottle. 
DNA storage buffer: 
0.5 M EDTA                          0.01 ml 
1 M tris                                      0.5 ml 
Final volume was made 50 ml with sterile distilled water. 
Lysis buffer 
1 M tris                                         2.0 ml 
0.5M EDTA                 400 μl 
10% SDS                      30.0 ml 
Final volume of the solution was made 100ml with sterile distilled water. 
Lysis solution 
1 M Ammonium chloride                 15.5 ml 
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1M Potassium bicarbonate                    1.0 ml 
0.5 M EDTA                                          200 μl 
Final volume was made 100 ml with sterile distilled water. 
Proteinase k 
Proteinase k                               10 mg 
Proteinase k was dissolved in 1 ml of deionized water and stored at -20˚C in aliquots 
of 
1 ml each. 
SE Solution 
5 M Sodium chloride                                3 ml 
0.5 M EDTA                                    8 ml 
Final volume was made 200ml with sterile distilled water. pH was adjusted to 8. 
SDS (10%) 
SDS                                            10 g 
SDS was dissolved in 100 ml sterile distilled water.  
Sodium acetate (3M) 
Sodium acetate                                40.83 g 
Sodium acetate was dissolved in 100 ml sterile distilled water; pH of the solution was 
adjusted to 5.0 using acetic acid. 
Saturated phenol 
0.2% β- mercaptoethanol 
8-hydroxy quinoline 
0.1 M Tris HCl buffer           800 ml 
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0.5 M Tris HCl buffer                           1000 ml 
Phenol                                     1000 ml 
The mixture obtained by adding equal volume of 0.5M Tris-Cl buffer and melted 
phenol was stirred for 15 min on magnetic stirrer. Two phases were allowed to 
separate. Upper aqueous phase was removed and equal volume of 0.1 M Tris-chloride 
buffer was added. The saturation with 0.1 M Tris-Cl buffer was repeated till 
phenol>7.8 pH was obtained. A pinch of β mercaptoethanol and 8-hydroxy quinoline 
was added. Phenol was stored at 4˚C in a dark bottle. 
REAGENTS FOR AGAROSE GEL ELECTROPHORESIS 
Agarose (1%) 
Agarose                                      1.0 g 
Buffer                                                     100 ml 
EtBr                                            5.0 μl 
Agarose was dissolved in a buffer and heated till a clear solution is formed. EtBr was 
then added to the solution. 
Bromophenol blue 
Bromophenol blue                                0.4 g 
Sucrose                                                20.0 g 
Bromophenol blue was dissolved in 100 ml of distilled water. 
From the above stock solution 31.25 ml was taken and sucrose was added. Final 
volume was made to 50 ml with distilled water. 
Ethidium bromide 
Ethidium bromide 10 mg 
Ethidium Bromide was dissolved in 1ml of distilled water. The solution was stored in 
a dark bottle at 4˚C.  
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50X TAE (pH 8.0) 
Tris base                                                         242 g 
0.5MEDTA                                    100 ml 
Glacial acetic acid                          57.1 ml 
Final volume was made 1000 ml with distilled water. 
1X TAE (pH 8.0) 
50 X TAE 20 ml 
Final volume was made 1000 ml with distilled water. 
REAGENTS FOR PCR 
Stock 
Deoxyribose nucleotide triphosphate (dNTP), 10mM each dATP, dGTP, dCTP, dTTP 
and Taq polymerase (5U/ml) 10X Taq buffer Primers: 100 mM in sterile demonized 
water (Sigma) 100bp DNA ladder (100μg/ml) 
EQUIPMENTS 
The details of equipments used during the course of study 
Equipments                                   Source 
Deep freezer (-20°C)                         Nirmal Instruments 
Centrifuge                                                  Avanti
TM
 
Spectrophotometer                                         ELICO 
Vortex mixer           Remi 
Hot plate                                           SHIV 
Magnetic stirrer                            SHIV 
Thermal cycler                      Eppendrof 
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Electrophoresis apparatus              BangloreGeni 
Power supply                                               Genei 
Uv-Tran Illuminator                            Hoeser 
Incubator                                        Techno 
Autoclave                                    Techno 
Refrigerator                                 Godrej 
Ph meter                        HANNA 
Gel documentation unit                 Alpha Innotech Corporation 
Stabilizer                                           Philips 
 
 
